Halozyme’s Spotlight Shifts To Enhanze Exclusively After PEGPH20 Fails In Phase III

SC1911_Spotlight_76770868_1200.jpg
After 160 job cuts and with an Enhanze-only focus, Halozyme will be profitable next year. • Source: Shutterstock
Scrip Podcast

Have you checked out Scrip podcast?

New episodes every Thursday.

More from Strategy

More from Business